Reviewer’s report

**Title:** VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma

**Version:** 2  **Date:** 28 January 2013

**Reviewer:** mingyong han

**Reviewer’s report:**

IN the manuscript, the question posed by the authors is defined. But the experimental methods only include tumor model and histology, these methods so simple to answer this question.

The results from this manuscript are 1, targeting the VEGF pathway is sufficient to inhibit progression of lung adenocarcinoma lesions in Kars "G12D-LSL" mice and components of vasculature and stroma are targeted by Als. the datas are not sound ,it should be at least include: 1 VEGF express level in serum and tumor tissue in tumor model; 2 VEGFR1,VEGFR2 express in the tumor tissue , and 3 their relationship with Als treatment.

**Declaration of competing interests:**

I declare that I have no competing interests